[Corrections] Correction to Lancet Infect Dis 2024; 25: e635–44

2nd Dec, 2025

Infectious Diseases

The Lancet

Paterson A, Mughogho KK, Cheyne A, et al. The (Re)-emerging And ePidemic Infectious Diseases (RAPID) Stigma Scales: a cross-outbreak scale development and psychometric validation study. Lancet Infect Dis 2025; 25: e635–44—In this Review, the study type should have been a psychometric validation study. This correction has been made as of Oct 24, 2025.

Published By: The Lancet

Infectious Diseases

15th Jan, 2026

The Lancet

[Clinical Picture] Unexpected finding in a 17-year-old female undergoing screening colonoscopy

Infectious Diseases

15th Jan, 2026

The Lancet

[Personal View] Azithromycin mass drug administration: balancing survival benefits and risks in children

Infectious Diseases

15th Jan, 2026

The Lancet

[Review] Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project

Infectious Diseases

15th Jan, 2026

The Lancet

[Series] Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship

Infectious Diseases

15th Jan, 2026

The Lancet

[Series] Innovation in active and passive immunisation of people who are immunocompromised: a call to action

Infectious Diseases

15th Jan, 2026

The Lancet

[Articles] Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories

Infectious Diseases

15th Jan, 2026

The Lancet

[Articles] A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial

[Corrections] Correction to Lancet Infect Dis 2024; 25: e635–44

Related Articles

[Clinical Picture] Unexpected finding in a 17-year-old female undergoing screening colonoscopy

[Personal View] Azithromycin mass drug administration: balancing survival benefits and risks in children

[Review] Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project

[Series] Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship

[Series] Innovation in active and passive immunisation of people who are immunocompromised: a call to action

[Articles] Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories

[Articles] A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial

[Corrections] Correction to Lancet Infect Dis 2024; 25: e635–44

Related Articles

[Clinical Picture] Unexpected finding in a 17-year-old female undergoing screening colonoscopy

[Personal View] Azithromycin mass drug administration: balancing survival benefits and risks in children

[Review] Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project

[Series] Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship

[Series] Innovation in active and passive immunisation of people who are immunocompromised: a call to action

[Articles] Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories

[Articles] A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial